Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pseudomonas aeruginosa injection dose-finding add-on to PD-1 antibody plus chemotherapy in first-line advanced NSCLC
ChiCTR2400093711Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2024
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of pseudomonas aeruginosa injection in non-small cell lung cancer (NSCLC) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Duration of remission, Disease control rate and 3 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
pseudomonas aeruginosa injection
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400093711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093711.